Newport Laboratories, Inc., a Boehringer Ingelheim company, is proud to announce the recipient of the first-ever Lex Thompson Veterinary Investigator Award. The award, which will be given annually to a veterinary student, recognizes an outstanding research proposal and provides the tools and support necessary to complete it.
The inaugural recipient is Luke Daniels of the University of Illinois, who plans to study the genetic diversity of Moraxella bovis, a bacterium that causes pinkeye in cattle.
“Looking ahead to the next generation of bovine health challenges is critical to ensuring veterinarians and producers have the tools and knowledge they need to address them,” said Randy Shirbroun, DVM, Director of the Ruminant Business Unit at Newport Laboratories. “So, who better to ensure the industry is keeping a watchful eye toward the future than the bright young minds who will be on the front lines of cattle health in the years to come?”
As the recipient of the award, Daniels will conduct his research with the support of Newport Labs technical service veterinarians and the company’s Diagnostics and Research and Development teams, in coordination with a cooperating professor or practicing veterinarian.
Daniels is a second-year veterinary student at the University of Illinois, where he serves as the college's AABP representative in the Production Medicine Club. In this role, he has organized wet labs and educational lectures regarding everything from cow-calf nutrition to dairy palpation labs. After graduation, he plans to continue learning about the different production systems found in the U.S. while working as a practitioner and maintaining his own production cattle operation.
“I’m honored to have been selected as the first recipient of the Lex Thompson Veterinary Investigator Award and excited to work with Newport Labs to answer some critical questions about Moraxella bovis, a pathogen that causes significant challenges for the cattle industry,” Daniels said.
The award was named after Dr. Lex Thompson, a longtime technical service veterinarian with Newport Labs. He was an enthusiastic, lifelong learner and exhibited an insatiable scientific curiosity. As a practitioner, Thompson enjoyed helping his clients, and later his veterinary colleagues, by digging into clinical and diagnostic problems to solve cattle health challenges. For the last several years of his life, Thompson fought a courageous battle against cancer, but ultimately passed away in March 2020. The Lex Thompson Veterinary Investigator Award recognizes students whose work exemplifies Thompson’s investigative initiative.
About Newport Laboratories
Newport Laboratories, Inc. is a Boehringer Ingelheim company and the nation’s leading manufacturer of custom-made vaccines. Located in Worthington, Minnesota, Newport Laboratories assists veterinarians and livestock producers in their efforts to address animal health problems through cutting-edge diagnostic testing and production of high-quality, evidence-based, custom-made vaccines. For further information, call 800-220-2522, email email@example.com, or visit the Newport Laboratories website at http://www.newportlabs.com.
Boehringer Ingelheim Animal Health
The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 9,700 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.
Respect for animals, humans and the environment guides us every day. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases.
Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of $4.7 billion (4.1 billion euros) in 2020 and presence in more than 150 countries.
Boehringer Ingelheim Animal Health has a significant presence in the United States, with more than 3,100 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit www.boehringer-ingelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH.
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim has been independent and family owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, with around 52,000 employees, we create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
In 2020, Boehringer Ingelheim achieved net sales of around $22.33 billion (19.57 billion euros). Our significant investment of over $4.2 billion (3.7 billion euros) in 2020 (18.9% of net sales) in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
The Newport Laboratories Logo® is a registered trademark of Newport Laboratories, Inc., an affiliate of Boehringer Ingelheim. ©2021 Newport Laboratories, Inc., Worthington, MN. All Rights Reserved. US-BOV-0259-2021